Must Reads by Date
Must reads for theWeek ending December 6, 2015
MRI Lesion Detection in Multiple Sclerosis, Comparing conventional and “advanced” techniques
IL-17A in Myasthenia Gravis, Studying associations with sex and disease severity
14bp Polymorphism in Multiple Sclerosis, Could it be a risk factor?
B Cells in Relapsing-Remitting Multiple Sclerosis, Revealing their coordination capabilities
Interferon Beta Stimulated Genes in Multiple Sclerosis, Could they be early biomarkers of treatment response?
Must reads for theWeek ending November 29, 2015
Pregnancy After NMOSD Onset, Studying risk factors for miscarriage
Brain Aging Toward Dementia, Assessing decline over time
CAG Expansion in Huntington Disease, Measuring its effect on motor, cognitive, and behavioral scores
Intravenous Methylprednisolone in MS and NMO, Evaluating the effects of subsequent courses
Neuromyelitis Optica Diagnostic Criteria, Assessing their clinical utility
Must reads for theWeek ending November 22, 2015
Cognitive Decline in Multiple Sclerosis, Assessing the effects of thalamus atrophy
Detecting Autoantibodies in Multiple Sclerosis, Evaluating the use of electrochemiluminescence assay
Cerebellar Growth in CNS Demyelinating Disease, Does age of onset correlate with volume loss?
Teriflunomide in Relapsing-Remitting MS, Comparing adverse events across studies
Escalation of Therapy in Neuromyelitis Optica Attacks, Do multiple courses of treatment affect outcomes?
Must reads for theWeek ending November 15, 2015
HRQOL Following Minor Ischemic Events, Predicting impairment at 3 months
Neurofilament Light Concentration in Alzheimer Disease, Studying associations with cognitive deterioration
Cerebral Amyloid Angiopathy in AD, Defining cognitive associations
Narcolepsy in African Americans, Does ethnicity affect sleep patterns?
Curative Surgery for Epileptic Spasms, Which procedures produce the best outcomes?
Must reads for theWeek ending November 8, 2015
Progressive Multifocal Leukoencephalopathy in MS, Evaluating the role of John Cunningham virus
Soluble CD26 and CD30 in MS, Assessing associations with immune responses
Alemtuzumab in Relapsing MS, Does clinical trial data hold up?
Cardiac Events in Fingolimod Initiation, Evaluating events in 850 episodes
Associations Between Symptoms, Community Integration, and Mental Health, Does MS type or level of progression define the patient?